Peripheral neuropathy induced by tislelizumab
10.3760/cma.j.cn114015-20220321-00221
- VernacularTitle:替雷利珠单抗致周围神经病变
- Author:
Quan WANG
1
;
Huaying TANG
1
;
Bing WANG
1
;
Jinfeng LI
1
Author Information
1. 山东大学附属威海市立医院药剂科，威海 264200
- Publication Type:Journal Article
- Keywords:
Peripheral nervous system diseases;
Immune checkpoint inhibitors;
Tislelizumab
- From:
Adverse Drug Reactions Journal
2023;25(4):255-256
- CountryChina
- Language:Chinese
-
Abstract:
A 62-year-old male patient with esophageal squamous cell carcinoma received immunotherapy combined with chemotherapy regimen (intravenous infusions of tislelizumab 200 mg on day 1, paclitaxel liposome 240 mg and nedaplatin 120 mg on day 2, 21 days as a cycle) for a total of 4 cycles. The patient′s condition was partially relieved. Then the treatment was changed to intravenous infusion of tislelizumab 200 mg on day 1 and tegafur, gimeracil and oteracil potassium 40 mg in the morning and 60 mg in the evening by mouth from the first day to the 14th day, 21 days as a cycle. Only one cycle was given. After the last treatment (the 98th day of immunotherapy combined with chemotherapy), the patient developed acute muscle weakness, sensory impairment, and decreased tendon reflexes. Nerve conduction and electromyography showed peripheral nerve damage in the limbs. Peripheral neuropathy caused by tislelizumab was considered. The patient received the treatments of methylprednisolone sodium succinate, mecobalamin, and vitamin B 1. Nine days later, his symptom of myasthenic was improved, and pain and warm sensation was recovered gradually. Since then, the patient had not been treated with immunotherapy.
